Novacyt, an international specialist in clinical diagnostics, announced the appointment of Paul Eros as Commercial Director of Primerdesign, effective from 1 November 2017.
Eros has more than thirty years’ of experience within the field of molecular diagnostics, including strategic global marketing, sales and product management. He joins Novacyt from DiaSorin, where he was VP of Molecular Marketing for more than five years.
Eros started his career with Becton Dickinson, quickly progressing through the sales and marketing organisation in both the UK and France, before joining Roche Diagnostics in 1999, where he held a number of senior international commercial and operational roles.
Eros’ appointment completes Novacyt’s investment in its senior commercial leadership team, building on the earlier Group appointments of Ruth Powell and Phil Sefton. Ruth Powell was appointed as Managing Director of the NovaPrep division and Phil Sefton as Managing Director of the Lab21 Products division.
Graham Mullis, Group CEO of Novacyt, said: “We are delighted to welcome Paul to the Company at this important juncture in our growth. We have made significant progress growing our business-to-business channel in Primerdesign and have already signed three new design prototyping and development contracts for Q4 2017.
“Paul’s considerable blue-chip commercial expertise specifically in molecular diagnostics will be hugely beneficial as we aim to convert our healthy pipeline of clinical projects and B2B opportunities into new contracts.
“We remain committed to investing in commercial expansion and I have been pleased with the important and early positive impact that Ruth and Phil have already made to the Group. I am confident that we have invested in a strong senior leadership team that can continue to drive growth from the many opportunities that we see.”
